Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Survivorship
Metadata
Title
Description, characterization, and evaluation of an online social networking community: the American Cancer Society’s Cancer Survivors Network®
Publication date
01-10-2018
Published in
Journal of Cancer Survivorship / Issue 5/2018
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-018-0706-8

Other articles of this Issue 5/2018

Journal of Cancer Survivorship 5/2018 Go to the issue

OriginalPaper

Insurance, chronic health conditions, and utilization of primary and specialty outpatient services: a Childhood Cancer Survivor Study report

OriginalPaper

Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016)

OriginalPaper

The relationship between physical impairments, quality of life and disability of the neck and upper limb in patients following neck dissection

OriginalPaper

Comorbid conditions and health-related quality of life in long-term cancer survivors—associations with demographic and medical characteristics

OriginalPaper

Identifying barriers to cancer survivors sharing their survivorship care plans with their healthcare provider

OriginalPaper

Impact of acculturation on breast cancer treatment and survivorship care among Mexican American patients in Texas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits